/
Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries. Company Background On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisitio…
$3.66
$0.13 (-3.43%)
Price from 14 days ago
12.58% operating margin is respectable but not wide. ROIC at 24.15%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 29.9% YoY with margins expanding 4.8pp.
Even for strong businesses, today's 17x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
17.4x earnings, 69.9x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$130M
▲ +29.9% YoY
Net Income (TTM)
$19M
▲ +103.3% YoY
Op. Margin
10.03%
▲ +4.8pp YoY
ROIC
15.74%
▲ +5.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▲ +11.5% YoY
Op. Cash Flow (TTM)
$4M
▲ +11.5% YoY
Net Debt
-$64M
Net Cash Position
Cash & Equiv.
$67M
5Y CAGR: +16.9%
Continue Research